Biosimilars Market

Biosimilars Market by Drug Class (Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Trastuzumab), Insulin, Erythropoietin, Anticoagulants. rhGH), Indication, Region Global Forecast to 2028

Report Code: PH 7582 Jun, 2023, by marketsandmarkets.com

The global biosimilars market in terms of revenue was estimated to be worth $29.4 billion in 2023 and is poised to reach $66.9 billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Rising incidence of chronic diseases, increasing demand for biosimilars due to cost-effectiveness, increased number of product pipelines and loss of patent exclusivity of blockbuster drugs is driving the market growth.

Attractive Opportunities in the biosimilars market

Biosimilars Market

To know about the assumptions considered for the study, Request for Free Sample Report

Biosimilars Market

Biosimilars Market Dynamics

DRIVER: Launch of novel biosimilars

Various key market players operating in the market have a strong emphasis on the development of biosimilars. As of December 2022, FDA has approved 40 biosimilars, and 25 have launched in the US. During the COVID-19 pandemic, FDA approvals slowed significantly; however, approvals rebounded in 2022, with seven new biosimilar approvals. All seven biosimilars approved in 2022 referenced products with previously approved biosimilars; no biosimilars were approved in 2022 referencing new reference products. 2022 also registered four new product launches, including the first two Lucentis (ranibizumab) biosimilars. Additionally, in 2022, FDA designated two new interchangeable biosimilars: Rezvoglar (referencing Lantus (insulin glargine)) and Cimerli (referencing Lucentis (ranibizumab)). Although there was an overall decline in approvals during the 2020 to 2021 timeframe, the number of development programs participating in the FDA’s Biosimilar Development Program has continued to rise. As of April 2023, there are around 60–70 biosimilars under pipeline studies. (Clinical.gov); half of them will be launched in three to four years. Growing approvals of biosimilars will ensure access to a greater pool of therapeutics and drive market growth.

RESTRAINT: Complexities in Manufacturing

Developing biosimilars is a highly complex and costly process that requires significant investments, technical capabilities, clinical trial expertise, scientific standards, and quality systems. Unlike the development of generic medicines, biosimilar manufacturers must invest in clinical trials and post-approval safety monitoring programs similar to that of the original innovator companies. Developing a biosimilar is a complex process. Biosimilars, like all biologics, are produced through an intricate, multistep process using living cells. However, the cell line and manufacturing process of the reference product are proprietary and belong to the original manufacturer.

For new entrants, the cost of developing biosimilars ranges from USD 100–250 million, including the cost of constructing a plant capable of producing biosimilars on a large scale. Besides this, the estimated timeframe for setting up a biosimilar/biological production capacity is anywhere from five to seven years; the cost can vary based on the location. The requirement for such high investments extends the time for companies to break even or to get sufficient returns on investment. In addition, companies with manufacturing experience (especially in biologics), such as Amgen and Biogen Idec, will have a considerable advantage over new companies with no such manufacturing experience. Hence, large pharmaceutical companies are expected to dominate the market as they bring marketing, sales, R&D, and manufacturing expertise.

OPPORTUNITY: Emerging markets

Markets across the Asia Pacific, Latin America (LATAM), and the Middle East offer significant growth opportunities to biosimilar manufacturers primarily due to the presence of less-stringent regulatory guidelines in developing countries. They differ from established markets regarding regulatory pathways, payer perceptions, pricing, affordability, and competitive landscapes. China and India are considered attractive destinations for R&D outsourcing for global biosimilar development and manufacturing companies, mainly due to their low labor & laboratory setup costs and the availability of skilled resources. This has drawn significant attention from key market players.

The market in Asia Pacific is a dynamic and rapidly evolving industry, with several key players leading the way: Celltrion (South Korea), Samsung Bioepis (South Korea), Dr. Reddy’s Laboratories (India), Biocon, and Shanghai Henlius Biotech (China). These companies have been instrumental in developing and commercializing biosimilars in the region and are expected to continue driving innovation and growth in the coming years..

CHALLENGE: Excess competition and regulatory challenges

Competition in the market is among biosimilar manufacturers and from originator biologic manufacturers. Upon the entry of new biosimilar products in the market, the originator biologic manufacturer may defend using various means such as the launch of second-generation products, reformulations, dosing improvements, supporting devices, and competing on prices.

Biosimilars Market Ecosystem

Biosimilars Market Ecosystem

The Oncology segment dominated the biosimilars industry in 2022.

Based on the indication, the biosimilars market is segmented into oncology, inflammatory and autoimmune diseases,  chronic diseases, blood disorders, growth hormone deficiency, infectious diseases, and other indications (infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, chronic kidney failure, and ophthalmic diseases). Oncology is the largest segment in this market owing to the availability of biosimilars at a lower price than innovative biologics and a large number of cancer patients. The availability of biosimilars in the field of oncology has lowered prices and made cancer treatment more affordable and accessible.  Also, due to the high incidence and prevalence of cancer, healthcare systems across the globe are focusing on reducing the burden of cancer by adopting cost effective treatment options. In this scenario, biosimilar drugs might witness widespread adoption in major markets such as the US, Europe, and the Asia Pacific. Considering these factors and the upending competition from biosimilars, many major biologic pharmaceutical companies are making significant investments in the development and approval of biosimilar drugs.

Monoclonal antibodies segment dominated biosimilars industry in 2022

Based on the product, the biosimilars market is segmented into monoclonal antibodies; insulin; Granulocyte Colony-Stimulating Factor; Erythropoietin; Recombinant Human Growth Hormone; Etanercept; Follitropin; Teriparatide; Interferons; anticoagulants; other drug class. Monoclonal antibodies accounted for a share. Insulin is segment has gained momentum in last few years, approvals for interchangebility is likely to project the growth of the segment. Launch of novel mabs biosimialrs in various regions coupled with substantial number of products under pipeline studies is likely to have positive impact on the growth of the market.

North America dominated the biosimilars industry in 2022.

Biosimilars Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Geographically, the biosimilars market is segmented Europe, the Asia Pacific, North America, Latin America and Middle East and Africa. In 2022, Europe accounted for the largest share of the market, followed by Asia Pacific & North America. Growth in these markets is primarily driven by several factors, such as the impending patent expiry of biologic products and the launch of new biosimilars, the rising incidence of chronic disorders, the emergence of new players and early entry into the market.

Key players in the biosimilars market include Novartis AG (Switzerland), Pfizer, Inc. (US), Dr. Reddy’s Laboratories Ltd. (India), Amgen, Inc. (US) and Eli Lilly and Company (US).

Scope of the Biosimilars Industry

Report Metric 

Details 

Market Revenue in 2023

$29.4 billion

Projected Revenue by 2028

$66.9 billion

Revenue Rate

Poised to Grow at a CAGR of 17.8%

Market Driver

Launch of novel biosimilars

Market Opportunity

Emerging markets

This report categorizes the biosimilars market to forecast revenue and analyze trends in each of the following submarkets:

By Drug Class

  • Monoclonal Antibodies
    • Infliximab
    • Trastuzumab
    • Rituximab
    • Adalimumab
    • Other monoclonal antibodies
  • Insulin
  • Granulocyte Colony-Stimulating Factor
  • Erythropoietin
  • Recombinant Human Growth Hormone
  • Etanercept
  • Follitropin
  • Teriparatide
  • Interferons
  • Anticoagulants
  • Other drug class

By Indication

  • Oncology
  • Inflammatory & Autoimmune Disorders
  • Chronic Diseases
  • Blood Disorders
  • Growth Hormone Deficiency
  • Infectious Diseases
  • Other Indications

By Region

  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Rest of Asia Pacific (RoAPAC)
  • North America
    • US
    • Canada
  • Latin America
  • Middle East and Africa

Recent Developments of Biosimilars Industry

  • In January 2023, Amgen Inc. launched AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab) in United States
  • In October 2022, Biocon and Yoshindo Inc., entered into an agreement for commercializing Biocon’s pipeline products ustekinumab and bDenosumab in Japan

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 33)
    1.1 STUDY OBJECTIVES 
    1.2 BIOSIMILARS INDUSTRY DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
          FIGURE 1 BIOSIMILARS MARKET SEGMENTATION
           1.3.1 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
    1.8 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 37)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 3 BIOSIMILARS MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 4 MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
          FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
          FIGURE 6 ILLUSTRATIVE EXAMPLE OF REVENUE SHARE ANALYSIS AND SEGMENTAL ANALYSIS, 2022
          FIGURE 7 ILLUSTRATIVE EXAMPLE OF REVENUE SHARE FOR DRUG CLASS & INDICATION, 2022
           2.2.1 INSIGHTS FROM PRIMARIES
                      FIGURE 8 MARKET VALIDATION FROM PRIMARY EXPERTS
                      FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    2.3 GROWTH RATE ASSUMPTIONS 
          FIGURE 10 MARKET: CAGR PROJECTIONS, 2023–2028
          FIGURE 11 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 12 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 MARKET: RECESSION IMPACT ANALYSIS 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2027 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2027 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
 
 
3 EXECUTIVE SUMMARY (Page No. - 51)
    FIGURE 13 BIOSIMILARS INDUSTRY, BY DRUG CLASS, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 BIOSIMILARS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 15 BIOSIMILARS INDUSTRY, BY REGION, 2023 VS. 2028 (USD MILLION)
 
4 PREMIUM INSIGHTS (Page No. - 54)
    4.1 BIOSIMILARS MARKET OVERVIEW 
          FIGURE 16 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: MARKET, BY DRUG CLASS AND COUNTRY (2022) 
          FIGURE 17 MONOCLONAL ANTIBODIES AND US TO DOMINATE NORTH AMERICAN MARKET
    4.3 MARKET: GEOGRAPHICAL SNAPSHOT 
          FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH OVER FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 57)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 19 BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 4 MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Increasing demand for biosimilars
                    5.2.1.2 Launch of novel biosimilars
                                FIGURE 20 US: NUMBER OF APPROVED AND LAUNCHED BIOSIMILARS, 2015 TO 2022
                    5.2.1.3 Rising geriatric population and chronic disease incidence
                                FIGURE 21 GERIATRIC POPULATION, BY REGION, 2020 VS. 2030 VS. 2050 (MILLION)
                                FIGURE 22 ESTIMATED NUMBER OF NEW CANCER CASES FROM 2020 TO 2030
                                FIGURE 23 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
                    5.2.1.4 Abbreviated regulatory approval process and interchangeability
                                TABLE 5 APPROVED BIOSIMILARS WITH INTERCHANGEABLE DESIGNATION
                                FIGURE 24 COMPARISON OF REFERENCE PRODUCTS, BIOSIMILARS, AND INTERCHANGEABLE PRODUCTS
           5.2.2 RESTRAINTS
                    5.2.2.1 Complexities in manufacturing
                                TABLE 6 COMPARISON OF DRUG DEVELOPMENT PROCESSES, BY TYPE
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging markets
                    5.2.3.2 Patent expiries of blockbuster biologics and research into new indications
                                TABLE 7 LIST OF KEY BIOLOGICS FACING PATENT EXPIRY
           5.2.4 CHALLENGES
                    5.2.4.1 High competition and regulatory challenges
    5.3 VALUE CHAIN ANALYSIS 
          FIGURE 25 VALUE CHAIN ANALYSIS FOR BIOSIMILARS
    5.4 ECOSYSTEM MARKET MAP 
          FIGURE 26 ECOSYSTEM MARKET MAP FOR BIOSIMILARS
    5.5 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 8 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.5.1 THREAT OF NEW ENTRANTS
           5.5.2 THREAT OF SUBSTITUTES
           5.5.3 BARGAINING POWER OF SUPPLIERS
           5.5.4 BARGAINING POWER OF BUYERS
           5.5.5 INTENSITY OF COMPETITIVE RIVALRY
    5.6 REGULATORY LANDSCAPE 
          TABLE 9 MARKET: REGULATORY LANDSCAPE
          TABLE 10 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
          TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 14 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.7 KEY CONFERENCES AND EVENTS, 2023 
          TABLE 15 MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2023
    5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 
          FIGURE 27 KEY STAKEHOLDERS IN BUYING PROCESS
          FIGURE 28 INFLUENCE OF END USERS ON BUYING PROCESS
    5.9 PATENT ANALYSIS 
    5.10 PIPELINE ANALYSIS 
    5.11 PRICING ANALYSIS 
           TABLE 16 BIOSIMILAR PRICE, BY INDICATION AND REGION
    5.12 TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
 
6 BIOSIMILARS MARKET, BY DRUG CLASS (Page No. - 83)
    6.1 INTRODUCTION 
          TABLE 17 BIOSIMILARS INDUSTRY, BY DRUG CLASS, 2021–2028 (USD MILLION)
    6.2 MONOCLONAL ANTIBODIES 
          TABLE 18 MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 19 MARKET FOR MONOCLONAL ANTIBODIES, BY REGION,  2021–2028 (USD MILLION)
          TABLE 20 NORTH AMERICA: MARKET FOR MONOCLONAL ANTIBODIES,  BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 21 EUROPE: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 22 ASIA PACIFIC: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.1 INFLIXIMAB
                    6.2.1.1 Infliximab to dominate mAbs market
                                TABLE 23 MARKET FOR INFLIXIMAB, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 24 NORTH AMERICA: MARKET FOR INFLIXIMAB, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 25 EUROPE: MARKET FOR INFLIXIMAB, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 26 ASIA PACIFIC:  MARKET FOR INFLIXIMAB, BY COUNTRY,  2021–2028 (USD MILLION)
           6.2.2 RITUXIMAB
                    6.2.2.1 Rising incidences of autoimmune diseases and cancer to boost market growth
                                TABLE 27 MARKET FOR RITUXIMAB, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 28 NORTH AMERICA: MARKET FOR RITUXIMAB, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 29 EUROPE: MARKET FOR RITUXIMAB, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 30 ASIA PACIFIC: MARKET FOR RITUXIMAB, BY COUNTRY,  2021–2028 (USD MILLION)
           6.2.3 TRASTUZUMAB
                    6.2.3.1 Increasing breast cancer prevalence to drive market growth
                                TABLE 31 MARKET FOR TRASTUZUMAB, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 32 NORTH AMERICA: MARKET FOR TRASTUZUMAB, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 33 EUROPE: MARKET FOR TRASTUZUMAB, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 34 ASIA PACIFIC:  MARKET FOR TRASTUZUMAB, BY COUNTRY,  2021–2028 (USD MILLION)
           6.2.4 ADALIMUMAB
                    6.2.4.1 Loss of patent exclusivity to drive research
                                TABLE 35 FDA APPROVAL AND EU LAUNCH STATUS OF BIOSIMILARS TO HUMIRA
                                TABLE 36 MARKET FOR ADALIMUMAB, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 37 NORTH AMERICA: MARKET FOR ADALIMUMAB, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 38 EUROPE: MARKET FOR ADALIMUMAB, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 39 ASIA PACIFIC: MARKET FOR ADALIMUMAB, BY COUNTRY,  2021–2028 (USD MILLION)
           6.2.5 OTHER MONOCLONAL ANTIBODIES
                    TABLE 40 MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 41 NORTH AMERICA: MARKET FOR OTHER MONOCLONAL ANTIBODIES,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 42 EUROPE: MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 43 ASIA PACIFIC: MARKET FOR OTHER MONOCLONAL ANTIBODIES,  BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 GRANULOCYTE COLONY-STIMULATING FACTOR 
           6.3.1 LAUNCH OF BIOSIMILARS TO PROMOTE MARKET GROWTH
                    TABLE 44 LIST OF APPROVED BIOSIMILARS FOR G-CSF
                    TABLE 45 MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 46 NORTH AMERICA: MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 47 EUROPE: MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 48 ASIA PACIFIC: MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 INSULIN 
           6.4.1 INCREASING INCIDENCE OF DIABETES TO DRIVE MARKET
                    TABLE 49 MARKET FOR INSULIN, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 50 NORTH AMERICA: MARKET FOR INSULIN, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 51 EUROPE: MARKET FOR INSULIN, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 52 ASIA PACIFIC: MARKET FOR INSULIN, BY COUNTRY,  2021–2028 (USD MILLION)
    6.5 ERYTHROPOIETIN 
           6.5.1 RISING INCIDENCE OF BLOOD DISORDERS TO AUGMENT MARKET GROWTH
                    TABLE 53 LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN
                    TABLE 54 MARKET FOR ERYTHROPOIETIN, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 55 NORTH AMERICA: MARKET FOR ERYTHROPOIETIN, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 56 EUROPE: MARKET FOR ERYTHROPOIETIN, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 57 ASIA PACIFIC: MARKET FOR ERYTHROPOIETIN, BY COUNTRY,  2021–2028 (USD MILLION)
    6.6 RECOMBINANT HUMAN GROWTH HORMONE 
           6.6.1 INCREASING INCIDENCE OF GROWTH DEFICIENCY DISORDERS TO PROPEL MARKET
                    TABLE 58 MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 59 NORTH AMERICA: MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 60 EUROPE: MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 61 ASIA PACIFIC: MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2021–2028 (USD MILLION)
    6.7 ETANERCEPT 
           6.7.1 APAC TO WITNESS HIGHEST GROWTH IN ETANERCEPT MARKET
                    TABLE 62 MARKET FOR ETANERCEPT, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 63 NORTH AMERICA: MARKET FOR ETANERCEPT, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 64 EUROPE: MARKET FOR ETANERCEPT, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 65 ASIA PACIFIC: MARKET FOR ETANERCEPT, BY COUNTRY,  2021–2028 (USD MILLION)
    6.8 FOLLITROPIN 
           6.8.1 INCREASING APPLICATION OF FOLLITROPIN IN INFERTILITY TREATMENT TO DRIVE MARKET
                    TABLE 66 MARKET FOR FOLLITROPIN, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 67 NORTH AMERICA: MARKET FOR FOLLITROPIN, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 68 EUROPE: MARKET FOR FOLLITROPIN, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 69 ASIA PACIFIC: MARKET FOR FOLLITROPIN, BY COUNTRY,  2021–2028 (USD MILLION)
    6.9 TERIPARATIDE 
           6.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS TO BOOST DEMAND
                    TABLE 70 MARKET FOR TERIPARATIDE, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 71 NORTH AMERICA: MARKET FOR TERIPARATIDE, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 72 EUROPE: MARKET FOR TERIPARATIDE, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 73 ASIA PACIFIC: MARKET FOR TERIPARATIDE, BY COUNTRY,  2021–2028 (USD MILLION)
    6.1 INTERFERONS 
           6.10.1 RISING INCIDENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH
                    TABLE 74 MARKET FOR INTERFERONS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 75 ASIA PACIFIC: MARKET FOR INTERFERONS, BY COUNTRY,  2021–2028 (USD MILLION)
    6.11 ANTICOAGULANTS 
           6.11.1 WIDE RANGE OF APPLICATIONS TO DRIVE DEMAND FOR ENOXAPARIN SODIUM BIOSIMILARS
                    TABLE 76 MARKET FOR ANTICOAGULANTS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 77 NORTH AMERICA: MARKET FOR ANTICOAGULANTS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 78 EUROPE: MARKET FOR ANTICOAGULANTS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 79 ASIA PACIFIC: MARKET FOR ANTICOAGULANTS, BY COUNTRY,  2021–2028 (USD MILLION)
    6.12 OTHER DRUG CLASSES 
          TABLE 80 MARKET FOR OTHER DRUG CLASSES, BY REGION,  2021–2028 (USD MILLION)
          TABLE 81 ASIA PACIFIC: MARKET FOR OTHER DRUG CLASSES, BY COUNTRY,  2021–2028 (USD MILLION)
 
7 BIOSIMILARS MARKET, BY INDICATION (Page No. - 123)
    7.1 INTRODUCTION 
          TABLE 82 BIOSIMILARS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
    7.2 ONCOLOGY 
           7.2.1 INCREASED APPROVALS AND LAUNCH OF BIOSIMILARS IN ONCOLOGY TO DRIVE MARKET
                    TABLE 83 MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 84 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 85 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 86 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
    7.3 INFLAMMATORY & AUTOIMMUNE DISEASES 
           7.3.1 CHANGES IN LIFESTYLES AND ENVIRONMENTAL CONDITIONS TO INCREASE DISEASE INCIDENCE
                    TABLE 87 MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 88 NORTH AMERICA: MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 89 EUROPE: MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 90 ASIA PACIFIC: MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 CHRONIC DISEASES 
           7.4.1 HIGH BURDEN OF CVD AND DIABETES WORLDWIDE TO DRIVE MARKET GROWTH
                    TABLE 91 BIOSIMILARS INDUSTRY FOR CHRONIC DISEASES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 92 NORTH AMERICA: MARKET FOR CHRONIC DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 93 EUROPE: MARKET FOR CHRONIC DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 94 ASIA PACIFIC: MARKET FOR CHRONIC DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
    7.5 BLOOD DISORDERS 
           7.5.1 INCREASING INCIDENCE OF BLOOD DISORDERS TO BOOST BIOSIMILAR DEMAND
                    TABLE 95 MARKET FOR BLOOD DISORDERS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 96 NORTH AMERICA: MARKET FOR BLOOD DISORDERS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 97 EUROPE: MARKET FOR BLOOD DISORDERS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 98 ASIA PACIFIC: MARKET FOR BLOOD DISORDERS, BY COUNTRY,  2021–2028 (USD MILLION)
    7.6 GROWTH HORMONE DEFICIENCY 
           7.6.1 RISING USE OF BIOSIMILARS FOR TREATMENT TO SUPPORT MARKET GROWTH
                    TABLE 99 MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 100 NORTH AMERICA: MARKET FOR GROWTH HORMONE DEFICIENCY,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 101 EUROPE: MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 102 ASIA PACIFIC: MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.7 INFECTIOUS DISEASES 
           7.7.1 MARKET FOR INFECTIOUS DISEASES TO GROW RAPIDLY IN ASIA PACIFIC
                    TABLE 103 MARKET FOR INFECTIOUS DISEASES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 104 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
    7.8 OTHER INDICATIONS 
          TABLE 105 MARKET FOR OTHER INDICATIONS, BY REGION,  2021–2028 (USD MILLION)
          TABLE 106 NORTH AMERICA: MARKET FOR OTHER INDICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 107 EUROPE: MARKET FOR OTHER INDICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 108 ASIA PACIFIC: MARKET FOR OTHER INDICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)
 
8 BIOSIMILARS MARKET, BY REGION (Page No. - 142)
    8.1 INTRODUCTION 
          TABLE 109 BIOSIMILARS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
    8.2 EUROPE 
          TABLE 110 EUROPE: LIST OF APPROVED BIOSIMILARS
          FIGURE 29 EUROPE: BIOSIMILARS MARKET SNAPSHOT
          TABLE 111 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 112 EUROPE: MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
          TABLE 113 EUROPE: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 114 EUROPE: BIOSIMILARS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
           8.2.1 GERMANY
                    8.2.1.1 Germany to dominate European biosimilars market
                                TABLE 115 GERMANY: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
                                TABLE 116 GERMANY: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 117 GERMANY: BIOSIMILARS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
           8.2.2 UK
                    8.2.2.1 Increasing adoption of biosimilars to boost market
                                TABLE 118 UK: LIST OF APPROVED BIOSIMILARS
                                TABLE 119 UK: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
                                TABLE 120 UK: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 121 UK: BIOSIMILARS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
           8.2.3 FRANCE
                    8.2.3.1 Rising geriatric population to drive market growth
                                TABLE 122 FRANCE: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
                                TABLE 123 FRANCE: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 124 FRANCE: BIOSIMILARS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
           8.2.4 ITALY
                    8.2.4.1 Favorable government policies to propel adoption of biosimilars
                                TABLE 125 ITALY: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
                                TABLE 126 ITALY: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 127 ITALY: BIOSIMILARS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
           8.2.5 SPAIN
                    8.2.5.1 Favorable patient incentives to promote biosimilar use
                                TABLE 128 SPAIN: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
                                TABLE 129 SPAIN: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 130 SPAIN: BIOSIMILARS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
           8.2.6 REST OF EUROPE
                    TABLE 131 REST OF EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
                    TABLE 132 REST OF EUROPE: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 133 REST OF EUROPE: BIOSIMILARS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
           8.2.7 EUROPE: RECESSION IMPACT
    8.3 ASIA PACIFIC 
          FIGURE 30 ASIA PACIFIC: BIOSIMILARS MARKET SNAPSHOT
          TABLE 134 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 135 ASIA PACIFIC: MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
          TABLE 136 ASIA PACIFIC: BIOSIMILARS INDUSTRY FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 137 ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
           8.3.1 CHINA
                    8.3.1.1 China to register highest growth in Asia Pacific market
                                TABLE 138 BIOSIMILARS APPROVED IN CHINA
                                TABLE 139 CHINA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
                                TABLE 140 CHINA: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 141 CHINA: BIOSIMILARS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
           8.3.2 SOUTH KOREA
                    8.3.2.1 Favorable government initiatives to support growth
                                TABLE 142 SOUTH KOREA: LIST OF APPROVED BIOSIMILARS
                                TABLE 143 SOUTH KOREA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
                                TABLE 144 SOUTH KOREA: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 145 SOUTH KOREA: BIOSIMILARS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
           8.3.3 INDIA
                    8.3.3.1 Increasing biosimilar launches and approvals to support market growth
                                TABLE 146 BIOSIMILARS APPROVED AND MARKETED IN INDIA
                                TABLE 147 INDIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
                                TABLE 148 INDIA: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 149 INDIA: BIOSIMILARS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
           8.3.4 JAPAN
                    8.3.4.1 Large geriatric population to drive market growth
                                TABLE 150 JAPAN: LIST OF APPROVED BIOSIMILARS
                                TABLE 151 JAPAN: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
                                TABLE 152 JAPAN: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 153 JAPAN: BIOSIMILARS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
           8.3.5 AUSTRALIA
                    8.3.5.1 Favorable regulatory changes and increasing disease incidence to propel growth
                                TABLE 154 AUSTRALIA: LIST OF APPROVED BIOSIMILARS
                                TABLE 155 AUSTRALIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
                                TABLE 156 AUSTRALIA: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 157 AUSTRALIA: BIOSIMILARS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
           8.3.6 REST OF ASIA PACIFIC
                    TABLE 158 NEW ZEALAND: LIST OF APPROVED BIOSIMILARS
                    TABLE 159 MALAYSIA: LIST OF APPROVED BIOSIMILARS
                    TABLE 160 SINGAPORE: LIST OF APPROVED BIOSIMILARS
                    TABLE 161 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS,  2021–2028 (USD MILLION)
                    TABLE 162 REST OF ASIA PACIFIC: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 163 REST OF ASIA PACIFIC: BIOSIMILARS INDUSTRY, BY INDICATION,  2021–2028 (USD MILLION)
           8.3.7 ASIA PACIFIC: RECESSION IMPACT
    8.4 NORTH AMERICA 
          TABLE 164 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 165 NORTH AMERICA: BIOSIMILARS INDUSTRY, BY DRUG CLASS, 2021–2028 (USD MILLION)
          TABLE 166 NORTH AMERICA: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 167 NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
           8.4.1 US
                    8.4.1.1 US to dominate North American biosimilars market
                                TABLE 168 US: LIST OF APPROVED BIOSIMILARS
                                TABLE 169 US: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
                                TABLE 170 US: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 171 US: BIOSIMILARS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
           8.4.2 CANADA
                    8.4.2.1 Favorable government initiatives to support market
                                TABLE 172 CANADA: LIST OF APPROVED BIOSIMILARS
                                TABLE 173 CANADA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
                                TABLE 174 CANADA: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 175 CANADA: BIOSIMILARS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
           8.4.3 NORTH AMERICA: RECESSION IMPACT
    8.5 LATIN AMERICA 
           8.5.1 RISING INCIDENCE OF CANCER TO DRIVE MARKET
                    TABLE 176 LATIN AMERICA: LIST OF APPROVED BIOSIMILARS
                    TABLE 177 LATIN AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION)
                    TABLE 178 LATIN AMERICA: MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 179 LATIN AMERICA: BIOSIMILARS INDUSTRY, BY INDICATION, 2021–2028 (USD MILLION)
           8.5.2 LATIN AMERICA: RECESSION IMPACT
    8.6 MIDDLE EAST AND AFRICA 
           8.6.1 FAVORABLE REGULATORY REFORMS AND INFRASTRUCTURAL DEVELOPMENT TO FAVOR MARKET GROWTH
                    TABLE 180 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY DRUG CLASS,  2021–2028 (USD MILLION)
                    TABLE 181 MIDDLE EAST AND AFRICA: MARKET FOR MONOCLONAL ANTIBODIES,  BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 182 MIDDLE EAST AND AFRICA: BIOSIMILARS INDUSTRY, BY INDICATION,  2021–2028 (USD MILLION)
           8.6.2 MIDDLE EAST AND AFRICA: RECESSION IMPACT
 
9 COMPETITIVE LANDSCAPE (Page No. - 216)
    9.1 INTRODUCTION 
    9.2 STRATEGIES ADOPTED BY KEY PLAYERS 
          FIGURE 31 BIOSIMILARS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
    9.3 REVENUE SHARE ANALYSIS 
          FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2023
    9.4 MARKET SHARE ANALYSIS 
          FIGURE 33 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
          TABLE 183 BIOSIMILARS MARKET: DEGREE OF COMPETITION
    9.5 COMPANY EVALUATION QUADRANT, 2022 
           9.5.1 STARS
           9.5.2 EMERGING LEADERS
           9.5.3 PERVASIVE PLAYERS
           9.5.4 PARTICIPANTS
                    FIGURE 34 BIOSIMILARS MARKET: COMPANY EVALUATION QUADRANT, 2022
    9.6 COMPETITIVE BENCHMARKING OF TOP 30 PLAYERS 
           9.6.1 COMPANY FOOTPRINT ANALYSIS (30 COMPANIES)
                    TABLE 184 BIOSIMILARS MARKET: COMPANY FOOTPRINT ANALYSIS
           9.6.2 PRODUCT FOOTPRINT ANALYSIS (30 COMPANIES)
                    TABLE 185 BIOSIMILARS MARKET: PRODUCT FOOTPRINT ANALYSIS
           9.6.3 REGIONAL FOOTPRINT ANALYSIS (30 COMPANIES)
                    TABLE 186 BIOSIMILARS MARKET: REGIONAL FOOTPRINT ANALYSIS
    9.7 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022 
           9.7.1 PROGRESSIVE COMPANIES
           9.7.2 STARTING BLOCKS
           9.7.3 RESPONSIVE COMPANIES
           9.7.4 DYNAMIC COMPANIES
                    FIGURE 35 BIOSIMILARS MARKET: COMPANY EVALUATION MATRIX FOR  START-UPS/SMES, 2022
    9.8 COMPETITIVE BENCHMARKING OF START-UPS/SMES 
          TABLE 187 BIOSIMILARS MARKET: DETAILED LIST OF KEY START-UPS/SMES
          TABLE 188 BIOSIMILARS MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
    9.9 COMPETITIVE SCENARIO AND TRENDS 
           9.9.1 PRODUCT LAUNCHES & APPROVALS
                    TABLE 189 BIOSIMILARS MARKET: PRODUCT LAUNCHES, JANUARY 2020–APRIL 2023
           9.9.2 DEALS
                    TABLE 190 BIOSIMILARS MARKET: DEALS, JANUARY 2020–APRIL 2023
           9.9.3 OTHER DEVELOPMENTS
                    TABLE 191 BIOSIMILARS MARKET: OTHER DEVELOPMENTS, JANUARY 2020–APRIL 2023
 
10 COMPANY PROFILES (Page No. - 231)
     10.1 KEY MARKET PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             10.1.1 NOVARTIS AG
                        TABLE 192 NOVARTIS AG: BUSINESS OVERVIEW
                        FIGURE 36 NOVARTIS AG: COMPANY SNAPSHOT (2022)
             10.1.2 PFIZER INC.
                        TABLE 193 PFIZER INC.: BUSINESS OVERVIEW
                        FIGURE 37 PFIZER INC.: COMPANY SNAPSHOT (2022)
             10.1.3 AMGEN INC.
                        TABLE 194 AMGEN INC.: BUSINESS OVERVIEW
                        FIGURE 38 AMGEN INC.: COMPANY SNAPSHOT (2022)
             10.1.4 DR. REDDY’S LABORATORIES LTD.
                        TABLE 195 DR. REDDY’S LABORATORIES LTD.: BUSINESS OVERVIEW
                        FIGURE 39 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2022)
             10.1.5 ELI LILLY AND COMPANY
                        TABLE 196 ELI LILLY AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 40 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022)
             10.1.6 TEVA PHARMACEUTICAL INDUSTRIES
                        TABLE 197 TEVA PHARMACEUTICAL INDUSTRIES: BUSINESS OVERVIEW
                        FIGURE 41 TEVA PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT (2022)
             10.1.7 FRESENIUS KABI AG
                        TABLE 198 FRESENIUS KABI AG: BUSINESS OVERVIEW
                        FIGURE 42 FRESENIUS KABI AG: COMPANY SNAPSHOT (2022)
             10.1.8 STADA ARZNEIMITTEL AG
                        TABLE 199 STADA ARZNEIMITTEL AG: BUSINESS OVERVIEW
                        FIGURE 43 STADA ARZNEIMITTEL AG: COMPANY SNAPSHOT (2022)
             10.1.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
                        TABLE 200 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW
                        FIGURE 44 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022)
             10.1.10 F. HOFFMANN-LA ROCHE LTD
                        TABLE 201 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
                        FIGURE 45 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2022)
             10.1.11 CELLTRION HEALTHCARE CO., LTD.
                        TABLE 202 CELLTRION HEALTHCARE CO., LTD.: BUSINESS OVERVIEW
                        FIGURE 46 CELLTRION HEALTHCARE CO., LTD.: COMPANY SNAPSHOT (2022)
             10.1.12 SAMSUNG BIOLOGICS
                        TABLE 203 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
                        FIGURE 47 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2022)
             10.1.13 COHERUS BIOSCIENCES
                        TABLE 204 COHERUS BIOSCIENCES: BUSINESS OVERVIEW
                        FIGURE 48 COHERUS BIOSCIENCES: COMPANY SNAPSHOT (2022)
             10.1.14 BIOCON
                        TABLE 205 BIOCON: BUSINESS OVERVIEW
                        FIGURE 49 BIOCON: COMPANY SNAPSHOT (2022)
             10.1.15 AMEGA BIOTECH
                        TABLE 206 AMEGA BIOTECH: BUSINESS OVERVIEW
             10.1.16 APOTEX INC.
                        TABLE 207 APOTEX INC.: BUSINESS OVERVIEW
             10.1.17 BIOCAD
                        TABLE 208 BIOCAD: BUSINESS OVERVIEW
             10.1.18 MABXIENCE
                        TABLE 209 MABXIENCE: BUSINESS OVERVIEW
             10.1.19 PROBIOMED
                        TABLE 210 PROBIOMED: BUSINESS OVERVIEW
             10.1.20 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.
                        TABLE 211 FUJIFILM KYOVA KIRIN BIOLOGICS CO., LTD.: BUSINESS OVERVIEW
             10.1.21 INTAS PHARMACEUTICALS LTD.
                        TABLE 212 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
             10.1.22 RELIANCE LIFE SCIENCES
                        TABLE 213 RELIANCE LIFE SCIENCES: BUSINESS OVERVIEW
             10.1.23 KASHIV BIOSCIENCES, LLC
                        TABLE 214 KASHIV BIOSCIENCES, LLC: BUSINESS OVERVIEW
             10.1.24 USV PRIVATE LIMITED
                        TABLE 215 USV PRIVATE LIMITED: BUSINESS OVERVIEW
             10.1.25 AMNEAL PHARMACEUTICALS, INC.
                        TABLE 216 AMNEAL PHARMACEUTICALS INC.: BUSINESS OVERVIEW
     10.2 OTHER PLAYERS 
             10.2.1 FORMYCON AG
             10.2.2 POLPHARMA BIOLOGICS GROUP
             10.2.3 AMPHASTAR PHARMACEUTICALS, INC.
             10.2.4 ALVOTECH
             10.2.5 UCB SA
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
11 APPENDIX (Page No. - 299)
     11.1 DISCUSSION GUIDE 
     11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     11.3 CUSTOMIZATION OPTIONS 
     11.4 RELATED REPORTS 
     11.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the biosimilars market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. The top-down and other approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the biosimilars market. The secondary sources referred to for this research study include publications from government sources, such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the World Health Organization (WHO), the National Institute for Health and Care Excellence (NICE), Health Canada, the Australian Government Department of Health, Ministry of Food and Drug Safety of the Republic of Korea(MFDS), the Brazilian Health Regulatory Agency (ANVISA), the Health Products Regulatory Authority (HPRA), the Japan Ministry of Health, Labour and Welfare, the Central Drugs Standard Control Organization (CDSCO), and the China National Medical Products Administration (NMPA). Secondary sources include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global biosimilars market, which was validated through primary research.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Biosimilars Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Top-down approach was used to estimate and validate the total size of the biosimilars market. This method was also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the biosimilars business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global Biosimilars market size: Bottom-up Approach

Biosimilars Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global Biosimilars market size: Top-Down Approach

Biosimilars Market Size, and Share

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

A biosimilar is a biological medicine highly similar to another already approved biological medicine (the 'reference medicine'). Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicine. They are the approved forms of original products and can be manufactured and marketed after the patent expiry of original biologics.

Key Stakeholders

  • Biopharmaceutical drug (biosimilars and biologics) manufacturers
  • Private equity companies and venture capital firms
  • Healthcare service providers (hospitals and independent physicians)
  • Health insurance payers
  • Research and consulting service firms
  • Contract research organizations (CROs)
  • Contract manufacturing organizations (CMOs)
  • Pharmaceutical and medical associations

Report Objectives

  • To define, describe, and forecast the global biosimilars market based on the drug class, indication and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall biosimilars market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as service launched, acquisitions, expansions, agreements, collaborations, and R&D activities in the biosimilars market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographic Analysis

  • Further breakdown of the Rest of Europe biosimilars market into respective countries
  • Further breakdown of the Rest of Asia Pacific biosimilars market into respective countries
  • Further breakdown of the Rest of Latin America biosimilars market into respective countries

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)

Company Information

  • An additional five company profiles
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
PH 7582
Published ON
Jun, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Biosimilars Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback